Skip to main content

Table 1 Baseline characteristics

From: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

  IRD (N = 127) RD (N = 217) p1
Sex, n (%) n = 127 n = 217  
 Male 72 (56.7%) 107 (49.3%) 0.219
 Female 55 (43.3%) 110 (50.7%)
Age (at treatment initiation), n (%) n = 127 n = 217  
  ≤ 65 57 (44.9%) 80 (36.9%) 0.004
 66–75 59 (46.5%) 89 (41.0%)
  > 75 11 (8.7%) 48 (22.1%)
 Median (min–max) 66.0 (41.0–84.0) 68.0 (41.0–90.0) 0.002
M-protein type, n (%) n = 126 n = 217  
 IgG 82 (65.1%) 132 (60.8%) 0.470
 IgA 22 (17.5%) 37 (17.1%)
 LC only 18 (14.3%) 42 (19.4%)
 Othera 4 (3.2%) 6 (2.8%)
Light chain type, n (%) n = 126 n = 216  
 Kappa 78 (61.9%) 142 (65.7%) 0.122
 Lambda 44 (34.9%) 73 (33.8%)
 Biclonal 4 (3.2%) 1 (0.5%)
ISS stage (at treatment initiation), n (%) n = 108 n = 175  
 Stage 1 51 (47.2%) 63 (36.0%) 0.136
 Stage 2 28 (25.9%) 62 (35.4%)
 Stage 3 29 (26.9%) 50 (28.6%)
ECOG performance status, n (%) n = 124 n = 197  
 0 19 (15.3%) 22 (11.2%) 0.093
 1 84 (67.7%) 120 (60.9%)
 2 19 (15.3%) 44 (22.3%)
 3–4 2 (1.6%) 11 (5.6%)
Creatinine level (umol/l), n (%) n = 126 n = 205  
  ≤ 176 118 (93.7%) 179 (82.5%) 0.092
  > 176 8 (6.3%) 26 (12.0%)
 Median (min–max) 88.0 (31.0–668.0) 90.0 (45.0–902.0) 0.340
Extramedullary mass, n (%) n = 127 n = 210  
 No 109 (85.8%) 196 (93.3%) 0.034
 Yes 18 (14.2%) 14 (6.7%)
Number of previous lines of treatment, n (%) n = 127 n = 217  
 1 73 (57.5%) 123 (56.7%) 0.823
 2 30 (23.6%) 54 (24.9%)
 3 11 (8.7%) 23 (10.6%)
 4 8 (6.3%) 8 (3.7%)
  ≥ 5 5 (3.9%) 9 (4.1%)
 Median (min–max) 1.0 (1.0–9.0) 1.0 (1.0–7.0) 0.979
Previous treatment, n (%) n = 127 n = 217  
 ASCT 79 (62.0%) 94 (43.3%) < 0.001
 PI (bortezomib or carfilzomib) 123 (96.9%) 198 (91.2%) 0.047
 Bortezomib 120 (94.5%) 195 (89.9%) 0.162
 Carfilzomib 6 (4.7%) 6 (2.8%) 0.371
 IMiD (lenalidomide or thalidomide or pomalidomide) 64 (50.4%) 120 (55.3%) 0.433
 Lenalidomide 22 (17.3%) 33 (15.2%) 0.648
 Thalidomide 55 (43.3%) 105 (48.4%) 0.373
 Pomalidomide 2 (1.6%) 0.136
Disease status, n (%) n = 120 n = 193  
 Relapsed 95 (79.2%) 134 (69.4%) 0.067
 Refractory 25 (20.8%) 59 (30.6%)
➣ Primary refractory 10 (40.0%) 25 (42.4%) 1.000
➣ Relapsed and refractory 15 (60.0%) 34 (57.6%)
  1. a “other” = IgD, IgM, Biclonal, Nonsecretory
  2. 1 p-value of Mann-Whitney U test for continuous variables, Fisher’s exact test for categorical variables